Where Editas Medicine Stands With Analysts
Portfolio Pulse from Benzinga Insights
Editas Medicine (NASDAQ:EDIT) has been evaluated by 4 analysts over the past three months, with a mix of bullish and indifferent ratings. The average 12-month price target is $11.75, down from a previous $14.00. Recent analyst actions include a buy rating from Jones Trading, a lowered equal-weight from Barclays, a lowered buy from Truist Securities, and a raised buy from B of A Securities. Editas Medicine is a clinical-stage genome editing company using CRISPR/Cas9 technology. Despite a significant revenue decline, the company maintains a strong net margin and low debt-to-equity ratio.
September 17, 2024 | 9:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Editas Medicine has received mixed analyst ratings with a new average price target of $11.75, down from $14.00. Recent analyst actions include a buy rating from Jones Trading and a raised buy from B of A Securities. Despite a significant revenue decline, Editas maintains a strong net margin and low debt-to-equity ratio.
The mixed analyst ratings and lowered average price target suggest a neutral short-term impact on Editas Medicine's stock price. The company's strong net margin and low debt-to-equity ratio are positive factors, but the significant revenue decline poses challenges. The recent buy ratings from Jones Trading and B of A Securities provide some support, balancing the overall outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100